Arman Altincatal
Overview
Explore the profile of Arman Altincatal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wechsler M, Rogers L, Canonica G, Bourdin A, Altincatal A, Hardin M, et al.
ERJ Open Res
. 2024 Dec;
10(6).
PMID: 39687390
https://bit.ly/3XSwX62.
2.
Busse W, Pavord I, Wechsler M, Davila I, Altincatal A, de Prado Gomez L, et al.
Chest
. 2024 Dec;
PMID: 39631682
No abstract available.
3.
Pavord I, Rabe K, Israel E, Szefler S, Brusselle G, Pandit-Abid N, et al.
J Allergy Clin Immunol Pract
. 2024 Oct;
13(1):132-142.
PMID: 39424189
Background: Remission is proposed as a multicomponent outcome for patients with severe asthma. Objective: This post hoc analysis of QUEST (NCT02414854) and TRAVERSE (NCT02134028) evaluated whether dupilumab treatment leads to...
4.
Maspero J, Antila M, Deschildre A, Bacharier L, Altincatal A, Laws E, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(12):3303-3312.
PMID: 39209068
Background: In phase 3 VOYAGE (NCT02948959; Evaluation of Dupilumab in Children With Uncontrolled Asthma), dupilumab showed clinical efficacy with an acceptable safety profile in children aged 6 to 11 years...
5.
Maspero J, Fiocchi A, Deschildre A, Bacharier L, Altincatal A, Laws E, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(11):3135-3138.e2.
PMID: 39127101
No abstract available.
6.
Phipatanakul W, Vogelberg C, Bacharier L, Dell S, Altincatal A, Gall R, et al.
Pediatr Pulmonol
. 2024 Jul;
59(11):2976-2983.
PMID: 39016623
Background: The phase 3 VOYAGE (NCT02948959) and open-label extension EXCURSION (NCT03560466) studies evaluated dupilumab in children (6-11 years) with uncontrolled moderate-to-severe asthma. This post hoc analysis assessed the efficacy and...
7.
Fox R, Cree B, De Seze J, Gold R, Hartung H, Jeffery D, et al.
Neurology
. 2024 Apr;
102(9):e209357.
PMID: 38648580
Background And Objectives: Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL...
8.
Pavord I, Casale T, Corren J, FitzGerald M, Deniz Y, Altincatal A, et al.
J Allergy Clin Immunol Pract
. 2024 Mar;
12(7):1763-1772.
PMID: 38555079
Background: Changes from baseline in fractional exhaled nitric oxide (FeNO) and blood eosinophil count (Eos) may be related to efficacy outcomes in dupilumab-treated patients with moderate-to-severe asthma. Objective: This post...
9.
Guilbert T, Tolcachier A, Fiocchi A, Katelaris C, Phipatanakul W, Begin P, et al.
J Asthma Allergy
. 2024 Mar;
17:143-159.
PMID: 38476213
Purpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 inflammation in multiple diseases. This post hoc analysis of...
10.
Papi A, Castro M, Corren J, Pavord I, Tohda Y, Altincatal A, et al.
Respir Med
. 2024 Jan;
224:107535.
PMID: 38272376
Background: TRAVERSE (NCT02134028), a phase 3 open-label extension study, assessed dupilumab safety and efficacy in patients with asthma aged ≥12 years who completed a previous dupilumab asthma study. This analysis...